Glimpazin-L 10 (Empagliflozin 10 mg + Linagliptin 5 mg Tablets):
Product Information
– Brand Name: Glimpazin-L 10
– Active Ingredients:
– Empagliflozin 10 mg
– Linagliptin 5 mg
– Form: Tablets
Therapeutic Class
– Antidiabetic agent (combination)
– SGLT2 inhibitor + DPP-4 inhibitor
Indications
– Treatment of type 2 diabetes mellitus
– Improves glycemic control
– Reduces risk of cardiovascular events
Dosage and Administration
– Adult dose: 1 tablet once daily, in the morning
– Take with or without food
Mechanism of Action
– Empagliflozin:
– Inhibits sodium-glucose cotransporter 2 (SGLT2)
– Reduces glucose reabsorption in kidneys
– Increases glucose excretion in urine
– Linagliptin:
– Inhibits dipeptidyl peptidase-4 (DPP-4)
– Increases incretin hormone levels
– Enhances insulin secretion and reduces glucagon levels
Benefits
– Effective glycemic control
– Reduced risk of cardiovascular events
– Convenient once-daily dosing
– Combination therapy for improved efficacy
Side Effects
– Common:
– Hypoglycemia (low blood sugar)
– Urinary tract infections
– Increased urination
– Thirst
– Headache
– Less common:
– Allergic reactions
– Increased risk of genital mycotic infections
– Increased risk of acute kidney injury
Contraindications
– Hypersensitivity to empagliflozin or linagliptin
– Severe kidney impairment (eGFR <30 mL/min/1.73 m²)
– End-stage renal disease (ESRD)
– Dialysis
– Pregnancy and lactation (caution advised)
Precautions
– Monitor blood sugar, kidney function, and liver enzymes regularly
– Inform doctor about concomitant medications
– Caution in patients with:
– Renal or hepatic impairment
– History of pancreatitis
– History of hypersensitivity reactions
